The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcome of receiving lenvatinib following immunotherapy in patients with advanced hepatocellular carcinoma.
Jennifer Gile
No Relationships to Disclose
Mathias Earl Palmer
No Relationships to Disclose
Michael H. Storandt
No Relationships to Disclose
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
Nguyen H. Tran
Honoraria - Helsinn Therapeutics (Inst); QED Therapeutics (Inst)
Consulting or Advisory Role - QED Therapeutics (Inst)
Research Funding - Exact Sciences
Amit Mahipal
Consulting or Advisory Role - AstraZeneca/MedImmune; QED Therapeutics; Taiho Oncology
Speakers' Bureau - AstraZeneca
Research Funding - Taiho Pharmaceutical